300 related articles for article (PubMed ID: 30906218)
1. Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia.
Wang L; Yang L; Yang Z; Tang Y; Tao Y; Zhan Q; Lei L; Jing Y; Jiang X; Jin H; Zou Q; Xian J; Zhang L
Int J Biol Sci; 2019; 15(4):882-894. PubMed ID: 30906218
[TBL] [Abstract][Full Text] [Related]
2. NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia.
Tang Y; Tao Y; Wang L; Yang L; Jing Y; Jiang X; Lei L; Yang Z; Wang X; Peng M; Xiao Q; Ren J; Zhang L
FASEB J; 2021 Feb; 35(2):e21192. PubMed ID: 33201521
[TBL] [Abstract][Full Text] [Related]
3. NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells.
Zou Q; Tan S; Yang Z; Zhan Q; Jin H; Xian J; Zhang S; Yang L; Wang L; Zhang L
Theranostics; 2017; 7(8):2289-2304. PubMed ID: 28740552
[TBL] [Abstract][Full Text] [Related]
4. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells.
Huang J; Sun M; Tao Y; Ren J; Peng M; Jing Y; Xiao Q; Yang J; Lin C; Lei L; Yang Z; Zhang L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675134
[TBL] [Abstract][Full Text] [Related]
6. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
7. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
8. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Du Pisani LA; Shires K
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
[TBL] [Abstract][Full Text] [Related]
10. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
12. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
[TBL] [Abstract][Full Text] [Related]
13. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.
Huang M; Garcia JS; Thomas D; Zhu L; Nguyen LX; Chan SM; Majeti R; Medeiros BC; Mitchell BS
Oncotarget; 2016 Nov; 7(46):74917-74930. PubMed ID: 27732946
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
15. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.
Sportoletti P; Varasano E; Rossi R; Mupo A; Tiacci E; Vassiliou G; Martelli MP; Falini B
Leukemia; 2015 Feb; 29(2):269-78. PubMed ID: 25179729
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience.
El-Gamal RAE; Hashem AE; Habashy DM; Abou Elwafa MAZ; Boshnak NH
Int J Lab Hematol; 2021 Feb; 43(1):68-75. PubMed ID: 32856429
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
19. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
von Palffy S; Thorsson H; Peña-Martínez P; Puente-Moncada N; Sandén C; Blom AM; Henningsson R; Juliusson G; King B; Landberg N; Lazarevic V; Orsmark-Pietras C; Rissler M; Rissler V; Ågerstam H; Järås M; Lilljebjörn H; Fioretos T
Blood Adv; 2023 Apr; 7(7):1204-1218. PubMed ID: 36383712
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
Falini B; Sportoletti P; Martelli MP
Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
